Camber Capital Management’s Myriad Genetics MYGN Stock Holding History

Camber Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$10.6M	Sell	2,000,000 -350,000	-15%	-$2.07M	1%	18
2025 Q1	$20.8M	Sell	2,350,000 -750,000	-24%	-$9.01M	0.74%	22
2024 Q4	$42.5M	Sell	3,100,000 -850,000	-22%	-$15.7M	0.98%	23
2024 Q3	$108M	Sell	3,950,000 -1,550,000	-28%	-$42M	3.44%	10
2024 Q2	$135M	Sell	5,500,000 -2,135,000	-28%	-$46.8M	3.72%	9
2024 Q1	$163M	Hold	7,635,000	–	–	3.99%	8
2023 Q4	$146M	Buy	7,635,000 +1,000,000	+15%	+$17.3M	3.72%	9
2023 Q3	$106M	Hold	6,635,000	–	–	3.51%	10
2023 Q2	$154M	Sell	6,635,000 -365,000	-5%	-$7.97M	5.01%	6
2023 Q1	$163M	Hold	7,000,000	–	–	5%	8
2022 Q4	$102M	Buy	7,000,000 +2,000,000	+40%	+$37.3M	3.48%	11
2022 Q3	$95.4M	Hold	5,000,000	–	–	2.92%	13
2022 Q2	$90.8M	Buy	5,000,000 +1,500,000	+43%	+$31.1M	3.94%	12
2022 Q1	$88.2M	Buy	3,500,000 +750,000	+27%	+$19.2M	3.19%	16
2021 Q4	$75.9M	Hold	2,750,000	–	–	2.61%	17
2021 Q3	$88.8M	Sell	2,750,000 -250,000	-8%	-$8.3M	2.73%	17
2021 Q2	$91.7M	Hold	3,000,000	–	–	3.09%	16
2021 Q1	$91.3M	Sell	3,000,000 -2,000,000	-40%	-$56.8M	3.13%	11
2020 Q4	$98.9M	Hold	5,000,000	–	–	3.47%	14
2020 Q3	$65.2M	Buy	5,000,000 +1,000,000	+25%	+$12.7M	3.44%	10
2020 Q2	$45.4M	Buy	4,000,000 +1,650,000	+70%	+$23.4M	2.6%	13
2020 Q1	$33.6M	Buy	2,350,000 +1,350,000	+135%	+$28.5M	2.01%	18
2019 Q4	$27.2M	Hold	1,000,000	–	–	1.39%	23
2019 Q3	$28.6M	Buy	+1,000,000	New	+$29.1M	1.51%	26
2018 Q3	–	Sell	-1,500,000	Closed	-$56.1M	–	28
2018 Q2	$56.1M	Hold	1,500,000	–	–	2.16%	22
2018 Q1	$44.3M	Hold	1,500,000	–	–	2.18%	19
2017 Q4	$51.5M	Sell	1,500,000 -500,000	-25%	-$16.9M	2.52%	16
2017 Q3	$72.4M	Sell	2,000,000 -1,000,000	-33%	-$28.5M	4.59%	7
2017 Q2	$77.5M	Sell	3,000,000 -1,325,000	-31%	-$28.1M	3.77%	10
2017 Q1	$83M	Buy	4,325,000 +265,000	+7%	+$4.7M	3.37%	7
2016 Q4	$67.7M	Buy	+4,060,000	New	+$73.5M	3.52%	12

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Camber Capital Management's MYGN Position: Q2 2025 in Review

Camber Capital Management reduced its Myriad Genetics (MYGN) stake by 15% in Q2 2025, selling an estimated $2.07M and leaving 2,000,000 shares worth $10.6M. The position accounts for 1% of the portfolio, ranked #18.

Camber Capital Management first reported a position in MYGN in Q4 2016 and has held it in 31 quarters since. The position peaked at $163M in Q1 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

Camber Capital Management held 2,000,000 shares of Myriad Genetics worth $10.6M as of Q2 2025.
Camber Capital Management sold 350,000 Myriad Genetics shares in Q2 2025, an estimated $2.07M.
Myriad Genetics made up 1% of Camber Capital Management's portfolio in Q2 2025, its #18 holding.
Camber Capital Management first reported a position in Myriad Genetics in Q4 2016 and has held it in 31 quarters since.
Camber Capital Management's Myriad Genetics position peaked at $163M in Q1 2024.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.